Employees: 125
Size Hansa Biopharma (HNSA.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $479M, the 176th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 47.88 on 18 Nov 2026.
Performance Over six months the shares gained 39.1%, against -9.3% for the median peer and +2.8% for the Sweden market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 68.9% over the last twelve months (peer median +9.4%); the operating margin is -190.3% (peer median 11.2%).
Valuation It trades at 14.9× enterprise value to sales against a peer median of 4.6× (3rd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +105%, so the hurdle is -110 pp: the price already allows for a slowdown.
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 302M | SEK 222M | SEK 171M | SEK 134M | SEK 155M |
| Revenue growth | — | +30% | +28% | -13% | — |
| Gross profit | SEK 189M | SEK 128M | SEK 77.7M | SEK 69.3M | SEK 116M |
| EBITDA | n/a | -SEK 484M | -SEK 591M | -SEK 780M | -SEK 556M |
| Net income | -SEK 800M | -SEK 534M | -SEK 807M | -SEK 832M | -SEK 611M |
| Free cash flow | SEK 520M | -SEK 549M | -SEK 675M | -SEK 756M | -SEK 506M |
| Capital expenditure | SEK 32.0M | SEK 0 | SEK 116,000 | SEK 284,000 | SEK 3.33M |
| Total debt | SEK 948M | SEK 939M | SEK 1.08B | SEK 867M | SEK 791M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HNSA.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +25.3% | -3.4% | 2nd highest of 21 |
| 6-month return | +39.1% | -9.3% | 3rd highest of 20 |
| Distance from 52-week high | -7.3% | -38.3% | 4th highest of 21 |
| Revenue growth (TTM) | +68.9% | +9.4% | highest of 20 |
| Operating margin | -190.3% | 11.2% | lowest of 19 |
| EV / Sales | 14.9× | 4.6× | 3rd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | -4.7% | 7.4% | 2nd least demanding of 9 |
| Growth delivered (Del g) | +105.3% | +2.2% | 2nd highest of 9 |
| Hurdle (Req g minus delivered) | -110.0 pp | +2.1 pp | least demanding of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | 10.9× | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | 2.0× | -3.8% | +0.7% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 16.6× | 24.8% | +126.7% |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 1.8× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | 8.8× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | 7.2× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | 10.8× | 44.1% | +1.0% |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |